Different studies have analyzed intervals of 1, 2, or 3 years, which correspond to the practices of different European countries (1 year for Germany, 1–2 years for the Netherlands, and 2–3 years for Finland) [47,62,63,64,65,66].A large-scale international study involving more than 2700 LS patients with MLH1, MLH2, or MSH6 mutations, out of a total of 16,000 colonoscopies, showed no difference in cancer incidence rates or CRC stage distribution according to the three surveillance modalities [67]. The gene discussed is MLH1; the disease is colorectal carcinoma.